Home  |  Contact

UniProtKB/Swiss-Prot P08709: Variant p.Arg364Gln

Coagulation factor VII
Gene: F7
Variant information

Variant position:  364
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Arginine (R) to Glutamine (Q) at position 364 (R364Q, p.Arg364Gln).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and polar (Q)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In FA7D; Harrow/Padua.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  364
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  466
The length of the canonical sequence.

Location on the sequence:   WGQLLDRGATALELMVLNVP  R LMTQDCLQQSRKVGDSPNIT
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         WGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNIT

Chimpanzee                    WGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNIT

Mouse                         WGQLLDRGATALELMSIEVPRLMTQDCLEHAKHSSNTPKIT

Rat                           WGQLLDRGATALELMVIEVPRLMTQDCLEHAKHSANTPRIT

Bovine                        WGQLLERGVTARKLMVVLVPRLLTQDCLQQSRQRPGGPVVT

Rabbit                        WGQLLYRGALARELMAIDVPRLMTQDCVEQSEHKPGSPEVT

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 213 – 466 Factor VII heavy chain
Domain 213 – 452 Peptidase S1
Glycosylation 382 – 382 N-linked (GlcNAc...) asparagine
Beta strand 358 – 365


Literature citations

Molecular defects in CRM+ factor VII deficiencies: modelling of missense mutations in the catalytic domain of FVII.
Bernardi F.; Liney D.L.; Patracchini P.; Gemmati D.; Legnani C.; Arcieri P.; Pinotti M.; Redaelli R.; Ballerini G.; Pemberton S.; Wacey A.I.; Mariani G.; Tuddenham E.G.D.; Marchetti G.;
Br. J. Haematol. 86:610-618(1994)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 354-412; VARIANTS FA7D ILE-358; GLN-364; PHE-370 AND ARG-402; VARIANT GLN-413;

Purification and characterization of factor VII 304-Gln: a variant molecule with reduced activity isolated from a clinically unaffected male.
O'Brien D.P.; Gale K.M.; Anderson J.S.; McVey J.H.; Miller G.J.; Meade T.W.; Tuddenham E.G.D.;
Blood 78:132-140(1991)
Cited for: VARIANT FA7D GLN-364;

Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7).
Marchetti G.; Patracchini P.; Gemmati D.; Derosa V.; Pinotti M.; Rodorigo G.; Casonato A.; Girolami A.; Bernardi F.;
Hum. Genet. 89:497-502(1992)
Cited for: VARIANTS FA7D GLN-364 AND PHE-370;

Detection of missense mutations by single-strand conformational polymorphism (SSCP) analysis in five dysfunctional variants of coagulation factor VII.
Takamiya O.; Kemball-Cook G.; Martin D.M.A.; Cooper D.N.; von Felten A.; Meili E.; Hahn I.; Prangnell D.R.; Lumley H.; Tuddenham E.G.D.; McVey J.H.;
Hum. Mol. Genet. 2:1355-1359(1993)
Cited for: VARIANTS FA7D GLN-139; TRP-139; ARG-160; GLU-197 AND GLN-364;

Mutation pattern in clinically asymptomatic coagulation factor VII deficiency.
Bernardi F.; Castaman G.; Pinotti M.; Ferraresi P.; di Iasio M.G.; Lunghi B.; Rodeghiero F.; Marchetti G.;
Hum. Mutat. 8:108-115(1996)
Cited for: VARIANTS FA7D TRP-283; LYS-325; VAL-358; GLN-364 AND GLU-402; VARIANT GLN-413;

Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene.
Herrmann F.H.; Wulff K.; Auerswald G.; Schulman S.; Astermark J.; Batorova A.; Kreuz W.; Pollmann H.; Ruiz-Saez A.; De Bosch N.; Salazar-Sanchez L.;
Haemophilia 15:267-280(2009)
Cited for: VARIANTS FA7D LEU-64; GLN-73; PHE-82; PHE-84 DEL; GLY-88; PRO-88; PRO-120; CYS-128; ASP-138; GLN-139; LYS-154; SER-156; SER-157; ARG-160; PHE-171; PRO-181; ASN-183; PHE-186; SER-189; LEU-194; THR-194; ARG-195; GLN-212; ASP-216; ASN-241; THR-251; ARG-254; TYR-254; PRO-264; THR-266; ASN-272; ASN-277; TRP-283; ILE-298; GLN-301; ASN-302; HIS-302; THR-304; VAL-304; CYS-307; HIS-307; MET-312; PHE-321; LYS-325; GLN-326; CYS-337; PHE-341; SER-343; SER-345; CYS-350; VAL-354; ILE-358; PRO-360; ARG-363; HIS-363; GLN-364; TRP-364; PHE-370; TRP-375; MET-384; THR-387; VAL-387; SER-388; CYS-391; SER-391; GLU-401; HIS-403; ASN-404; GLY-413; MET-419; PHE-422; ALA-425; CYS-425; THR-429; ASP-432; GLU-435 AND PHE-437;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.